A review of quality-of-life evaluations in patients with congestive heart failure

PharmacoEconomics

Volumn 16, Issue 3, 1999, Pages 247-271

  Berry, Colin ^a   McMurray, John ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; HOSPITALIZATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REVIEW; WELLBEING;

HEART FAILURE, CONGESTIVE; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0032877407     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916030-00003     Document Type: Review

References (142)

1. 1. Patterson JA, Naughton J, Pietras RJ, et al. Treadmill exercise in assessment of the functional capacity of patients with cardiac disease. Am J Cardiol 1972; 30: 757-62
2. 2. Wenger NK. Quality of life: can it and should it be assessed in patients with chronic heart failure. Cardiology 1989; 76: 391-8
3. 3. Ghali JK, Cooper R, Ford E. Trends in hospitalisation rates for heart failure in the United States 1973-1986: evidence for screening population prevalence. Arch Intern Med 1992: 150: 769-73
4. 4. Ho KKL, Anderson KM, Karmel WB, et al. Survival after the onset of congestive heart failure in the Framingham Heart Study subjects. Circulation 1993; 88: 107-15
5. 5. Calman KC. Quality of life in cancer patients: an hypothesis. J Med Ethics 1984; 10: 124-7
6. 6. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987; 40: 593-600
7. 7. Bennett SJ, Baker SL, Huster GA. Quality of life in women with heart failure: health care for women international. Health Care Women Int: 1998; 19: 217-29
8. 8. Chin MH, Goldman L. Gender differences in 1-year survival and quality of life among patients admitted with congestive heart failure. Med Care 1998; 36 (7): 1033-6
9. 9. Konstam V, Salem D, Pouleur H, et al. Baseline quality of life as a predictor of mortality and hospitalisation in 5,025 patients with congestive heart failure. Am J Cardiol 1996; 78: 890-5
10. 10. McCullough LB. Concept of the quality of life: a philosophical analysis. In: Wenger NK, Le Jaq, editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York (NJ): Le Jacq Publishing, 1987: 25-45
11. 11. Bulpitt CJ. Quality of life with ACE inibitors in chronic heart failure. J Cardiovasc Pharmacol 1996; 27 Suppl. 2: S31-5
12. 12. Taylor SH. Congestive heart failure: towards a comprehensive treatment. Eur Heart J 1996; 17 Suppl. B: 43-56
13. 13. Bulpitt CJ. Quality of life as an outcome measure. Postgrad Med J 1997; 73: 613-6
14. 14. Jafri SM, Lakier JB, Rosman HS, et al. Symptoms and tests of ventricular performance in the evaluation of chronic heart failure. Am Heart J 1986; 112: 194-6
15. 15. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive cardiac failure: results of the Cooperative North Scandinavian Enalapril Survival Study Group (CONSENSUS). N Engl J Med 1987; 316: 1429-35
16. 16. Lipicky RJ, Packer M. Role of surrogate endpoints in the evaluation of drugs for heart failure. J Am Coll Cardiol 1993; 22: 179A-84A
17. 17. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA 1989; 262: 907-13
18. 18. Cleland JGF, Cowburn PJ, McMurray JJV. Heart failure: a systematic approach for clinical practice. London: Science Press, 1997: 5-7
19. 19. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102
20. 20. Obermann A. Role of quality of life assessment in clinical trials. In: Wenger N, Mattson ME, Furberg CD, et al., editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jaq, 1984: 67-86
21. 21. Ware JE. Methodological considerations in the selection of health status assesment procedures: role of quality of life assessment in clinical trials. In: Wenger N, Mattson ME, Furberg CD, et al., editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jaq. 1984: 67-86
22. 22. Stewart Al, Ware JE, editors. Measuring functioning and well-being. London: Duke University Press, 1992
23. 23. Spilker B. Guide to clinical trials. New York: Raven Press, 1991
24. 24. Spilker B. Quality of life assessments in clinical trials. New York: Raven Press, 1990
25. 25. Walker SR, Rosser RM, editors. The Quality of Well-Being Scale: rationale for a single quality of life index. Quality of life assessment: key issues in the 1990's. London: MTM Press, 1993: 65-94
26. 26. von Neumann J, Morgensten O. Theory of games and economic behaviour. 3rd ed. New York: Wiley, 1953
27. 27. La Puma, Lawlor E. Quality-adjusted life years: ethical implications for physicians and policymakers. JAMA 1990; 263 (21): 2917-21
28. 28 A symposium proceedings from the Second International Heart Failure Workshop. Am J Cardiol 1991; 67: 45C-7C
29. 29. Rawles J. Castigating QUALYs. J Med Ethics 1989; 15: 143-7
30. 30. Waller DG. Effect of drug treatment on quality of life in mild to moderate heart failure. Drug Saf 1991; 6 (4): 241-6
31. 31 Mayou R. Quality of life in CHF: is it more important than prolonged survival? A psychiatrist's perspective. Controversies Cardiol 1995: 9-12
32. 32. Feinstein AR. Clinimetrics. New Haven: Yale University Press, 1987
33. 33. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297-334
34. 34. Baligadoo SJ, Subratty H, Manraz M, et al. Effects of enoximone on quality of life. Int J Cardiol 1990; 28 Suppl. 1: S29-32
35. 35. Ganiats-TG, Browner DK, Dittrich HC. Comparison of Quality of Well-Being Scale and NYHA functional status classification in patients with atrial fibrillation. Am Heart J 1998; 135 (5 Pt. 1): 819-24
36. 36 Bulpitt CJ, Fletcher AE. Measurement of the quality of life in congestive heart failure-influence of drug therapy. Cardiovasc Drugs Ther 1988; 2: 419-24
37. 37. Goldman L, Hashimoto B, Cook FE, et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981; 64: 1227-34
38. 38. Aaronson NK. Assessing the quality of life of patients in cancer clinical trials: common problems and common sense solutions. Eur J Cancer 1992; 28A (8/9): 1304-6
39. 39. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life clinical trials. Can Med Assoc J 1986; 134: 889-95
40. 40. Barnett DB. Assessment of quality of life. Am J Cardiol 1991; 67: 41C-4C
41. 41. Eriksson H, Svarsudd K, Larsson B, et al. Quality of life in early heart failure. Scand J Prim Health Care 1988; 6: 161-7
42. 42. Guyatt GM. Methodologic problems in clinical trials in heart failure. J Chronic Dis 1985; 38: 353-63
43. 43. Packer M. The placebo effect in heart failure. Am Heart J 1990; 120: 1759-82
44. 44. Feldman Am, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl Med J 1993; 329: 149-55
45. 45. Harwood R. Quality of life in heart failure treated with enoximone [letter]. Br Heart J 1994; 72: 584
46. 46. Fletcher AE, Bulpitt CJ. Measurement of quality of life in clinical trials of therapy. Cardiology 1988; 75 Suppl. 1: 41-52
47. 47. Gallina A, Giacomarra G, Preveti A, et al. Comparison of patient's points of view on quality of life in cases of congestive heart failure [abstract]. Heart Failure Soc 1998; Sep 13-6: 126
48. 48. Jachuck SJ, Brierly H, Jachuck S, et al. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 1982; 32; 103-5
49. 49. Kazis LE, Anderson JJ, Meenan RF. Effect size for interpreting changes in health status. Med Care 1989; 27: S178-89
50. 50. Kong SX, Ghandi SK. Methodologic assessments of quality of life in clinical trials. Ann Pharmacother 1997; 31: 830-6
51. 51. Sanders C, Egger M, Donovan J, et al. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998; 317: 1191-4
52. 52. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994; 272: 619-25
53. 53. Begg CB, Cho M, Eastwood S, et al. Improving the quality reporting of randomised controlled trials: the CONSORT statement. JAMA 1996; 276: 637-9
54. 54. Guyatt GH, Cook DJ. Health status, quality of life, and the individual. JAMA 1994; 272 (8): 630-1
55. 55. Bergener M, Bobbitt RA, Kressel S, et al. The sickness impact profile: conceptual formulation and methodology for the development of health status measure. Int J Health Serv 1976; 6: 393
56. 56. Bergener M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805
57. 57. Katz S, Ford A, Moskowitz RW, et al. Studies of illness in the aged: the index of ADL. JAMA 1963; 185: 914
58. 58. Jones PW, Baveystock CM, Littlejohns P. Relationships between general health measured with the Sickness Impact Profile and respiratory symptoms, physiological measures and mood in patients with chronic airflow limitation. Ann Rev Resp Dis 1989; 140: 1538-43
59. 59. Jones PW. Quality of life measurement for patients with diseases of the airways. Thorax 1991; 46: 676-82
60. 60. Wu AW, Damiano Am, Lynn J, et al. Predicting future functional status for seriously ill hospitalised adults: the SUPPORT prognostic model. Ann Intern Med 1995; 122 (5): 342-50
61. 61. Fletcher A, McLoone P, Bulpitt C. Quality of life on angina therapy: a randomised controlled trial of transdermal glyceryl trinitrate against placebo. Lancet 1988; II: 4-7
62. 62. Rector TS, Francis GS, Conn JN. Patients' self-assessment of their congestive heart failure. Heart Fail 1987; 3: 198-209
63. 63. Rector TS. Usefulness of OPC-8212, a quinolone derivative, for chronic congestive hear failure in patients with ischaemic heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1991; 68 (11): 1203-10
64. 64. Bulpitt CJ, Fletcher AE, Dossenger L, et al. Quality of life in chronic heart failure: cilazapril and captopril versus placebo. Heart 1998; 79: 593-8
65. 65. Dossenger L, on behalf of the Cilazapril-Captopril Multicenter Group. Comparison of the effects of cilazapril and captopril against placebo on exercise testing in chronic heart failure patients: a double-blind, randomised, multicentre trial. Cardiology 1995; 86 Suppl. 1: 34-40
66. 66. Tyni-Lenne R, Gordon A, Jansson E, et al. Skeletal muscle endurance training impreoves peripheral oxidative capacity, exercise tolerance, and health-related quality of life in women with chronic congestive heart failure secondary to either ischaemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 80: 1025-9
67. 67. Tyni-Lenne R, Gordon A, Sylven C. Improved quality of life in chronic heart failure patients following local endurance training with leg muscles. J Card Fail 1996; 2 (2): 111-7
68. 68. Gordon A, Tyni-Lenne R, Jansson-Nordheim E, et al. Improved ventilation and decreased sympathetic stress in chronic heart failure patients following local endurance training with leg muscles. J Card Fail 1997; 3 (1): 3-11
69. 69. Tyni-Lenne R, Gordon A, Europe E, et al. Exercise-based rehabilitation improves skeletal muscle oxidative capacity, exercise tolerance and quality of life in both women and men with chronic heart failure. J Card Fail 1998; 4 (1): 9-17
70. 70. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF 36): conceptual framework and item selection. Med Care 1992; 30: 473-85
71. 71. Ware Jr JE, Bayliss MS, Rogers WH, et al. Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for service systems: results from the Medical Outcomes Study. JAMA 1996; 276 (13): 1039-47
72. 72. Jenkinson C, Coulter A, Wright L. Short form 36 (SF-36) health survey questionnaire: normative data for adults of working age. BMJ 1993; 306: 1437-40
73. 73. Garratt AM, Ruta DA, Abdalla MI, et al. The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 1993; 306: 1440-4
74. 74. Brazier JE, Harper R, Jones NMB, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305: 160-4
75. 75. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user manual. Boston (MA): Health Institute, New England Medical Center, 1994
76. 76. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1995; 34: 220-33
77. 77. Jenkinson C, Layte R. Development and testing of the UK SF-12. J Health Serv Res 1997; 2 (1): 14-8
78. 78. Jenkinson C, Layte K, Jenkinson D, et al. A shorter health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies. J Pub Health Med 1997; 19 (2): 179-86
79. 79. Ni H, Nauman DJ, Burgess D, et al. Comparison of SF-12 and Minnesota Living with Heart Failure Questionnaire regarding their sensitivities to the effect of program interventions on restoring quality of life [abstract 212]. Heart Failure Soc 1998; 212: 13-6
80. 80. Blyth FM, Lazarus R, Ross D, et al. Burden and outcomes of hospitalisation for congestive heart failure. Med J Aust 1997; 167: 67-50
81. 81. Komaroff Al, Fagioli LR, Doolittle TH, et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med 1996; 101 (3): 281-90
82. 82. Jenkinson C, Jenkinson D, Shepperd S, et al. Evaluation of treatment for congestive heart failure in patients aged 60 years and older using generic measures of health status (SF36 and COOP charts). Age Ageing 1997; 26: 7-13
83. 83. Rector TS, Ormaza SM, Kubo S. Health status of heart transplant recipients versus patients awaiting heart transplantation: a preliminary study of the SF-36 questionnaire. J Heart Lung Transplant 1993; 12: 983-60
84. 84. Rogers WJ, Johnstone DE, Yusuf S, et al. Quality of life among 5025 patients with left ventricular dysfunction randomised between placebo and enalapril: the studies of left ventricular dysfunction. J Am Coll Cardiol 1994; 23: 393-400
85. 85. Charlson ME, Pompei P, Aies K, et al. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83
86. 86. Hunt SM, MCKenna SP, McEwen J, et al. A quantitative approach in percieved health status: a validation study. J Epidemiol Commun Health 1980; 34: 281-6
87. 87. Hunt SM, McEwen J, McKenna SP. Perceived health: age and sex norms in a community. J Epidemiol Commun Health 1984; 38: 156-60
88. 88. Wiklund I, Romanus B, Hunt SM. Self-assessed disability in patients with arthrosis of the hip joint: reliability of the Swedish version of the Nottingham Health Profile. Int Disabil Stud 1988; 10: 159-63
89. 89. Wiklund I. The Nottingham Health Profile: a measure of health-related quality of life. Scand J Prim Health Care 1990; 1 Suppl. 1: 15-8
90. 90. Visser MC, Fletcher AE, Parr G, et al. A comparison of three quality of life instruments in patients with angina pectoris: the Sickness Impact Profile, the Nottingham Health Profile, and the Quality of Well Being Scale. J Clin Epidemiol 1994; 47: 157-63
91. 91. Ekeberg O, Klemsdal TO, Kjeldsen SE. Quality of life on enalapril after acute myocardial infarction. Eur Heart J 1994; 15 (8): 1135-9
92. 92. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Br Heart J 1994; 72: 226-30
93. 93. Guyatt GH, Nogradi S, Harlow S, et al. Develpment and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989; 4: 101-7
94. 94. Goodyer L, Miskelly F, Milligan P. Does encouraging good compliance improve patients' clinical condition in heart failure? Br J Clin Prac 1995; 49 (4): 173-6
95. 95. Johnson PH, Cowley AJ, Kinnear WJM. A randomised controlled trial of respiratory muscle training in stable chronic heart failure. Eur Heart J 1998; 19: 1249-53
96. 96. Kaplan RM, Bush JW, Berry CC. Health status: types of validity for an index of well-being. Health Serv Rev 1976; 11: 478-507
97. 97. Fanshel S, Bush JW. A health status index and its applications to health-services outcomes. Oper Res 1970; 18: 1021-66
98. 98. Anderson JP, Kaplan RM, Berry CC, et al. Interday reliability of function assessment for a health status measure: the Quality of well-being scale. Med Care 1989; 27: 1076-84
99. 99. Kaplan RM, Anderson, Ganiats TG. The Quality of Well Being Scale: rationale for a single quality of life index. In: Walker SR, Rosser RM, editors. Quality of life assessment: key issues in the 1990's. London: MTM Press, 1993: 65-94
100. 100. Tandon PK, Stander H, Dyke SH, et al. Assessment of quality of life of patients with heart failure: a randomised, controlled drug trial. Heart Fail 1988; 4: 39-54
101. 101. Tandon PK, Stander H, Schwarz RP. Analysis of quality of life data from a randomised, placebo-controlled heart failure trial. J Clin Epidemiol 1989; 42 (10): 955-62
102. 102. Rosen RC, Contrada RJ, Gorkin L, et al. Determinants of percieved health in patients with left ventricular dysfunction: a structural modelling analysis. Psychosomatic Med 1997; 59: 193-200
103. 103. Rector TS, Kubo SH, Cohn JN. Patient's self assessment of their congestive heart failure: content, reliability, and validity of a new measure: the Minnesota Living with Heart Failure questionnaire. Heart Fail 1987; 3: 198-219
104. 104. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. Circulation 1997; 96: 856-63
105. 105. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin and an angiotensin converting enzyme inhibitor? Circulation 1992; 88: 492-501
106. 106. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation 1992; 85: 942-9
107. 107. Colucci WS, Packer M, Bristow MR, the US Carvedilol Heart Failure Study Group, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800-6
108. 108. Cohn JN, Fowler MB, Bristow MR, the US Carvedilol Heart Failure Study Group, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997; 3 (3): 173-9
109. 109 Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-16
110. 110. Packer M, Colucci WS, Sackner-Bernstein JD, the PRECISE Study Group, et al. Double blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 1996; 94: 2793-9
111. 111. Gundersen T, Wiklund I, Sedberg K, et al. Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Cardiovasc Drugs Ther 1995; 9: 589-94
112. 112. Wiklund I, Waagstein F, Swedberg K, et al. Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Cardiovasc Drugs Ther 1996; 10: 361-8
113. 10 as an adjunctive in the treatment of chronic congestive heart failure. J Card Fail 1995; 1 (2): 101-7
114. 114. Guyatt GH, Sullivan MJJ, Fallen E, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1988; 61: 371-5
115. 115. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10
116. 116. Rector TS, Johnson G, Dunkman WB. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. Circulation 1993; 87 Suppl. VI: V71-I76
117. 117. Gorkin L, Norvell NK, Rosen R, et al. Assessment of quality of life as observed from the baseline data of the studies of left ventricular dysfunction trial quality of life substudy. Am J Cardiol 1993; 71: 1069-73
118. 118 Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomised, double blind, placebo-controlled trial of pimobendan. Am Heart J 1992; 124: 1017-25
119. 119. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart failure Questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993; 71: 1106-7
120. 120. Weilenmann D, Brunner-La Rocca HP, Candinas R, et al. Relation between quality of life and severity of heart failure in patients with mild to moderate congestive heart failure [abstract]. Heart Failure Soc 1998; Apr: 1315
121. 121. Rector TS, Tschumperlin LK, Kubo SH, et al. Use of the Living With Heart Failure Questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. J Card Fail 1995; 1 (3): 201-6
122. 122. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular fractions and congestive heart failure. N Engl J Med 1992; 327: 685-91
123. 123. Dorszewski A, Gohmann E, Dorszewski B, et al. Vasodilation by uradipil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not benefical: results of a placebo controlled, double blind study. J Card Fail 1997; 3: 91-6
124. 124. Cesario D, Clark J, Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J 1998; 135: 121-9
125. 125. Sanderson JE, Chan SKW, Yu CM, et al. β-Blockers in heart failure: a comparison of a vasodilating β-blocker with metoprolol. Heart 1998; 79: 86-92
126. 126. Pollock SG, Lystach J, Tedesco C, et al. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990; 66 (5): 603-7
127. 127. Metra M, Nardi M, Giubbini R, et al. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994; 24 (7): 1678-87
128. 128. Rector TS. Measurement of clinical efficacy in studies of heart failure. Circulation 1998; 97: 707-10
129. 129. Wilson JR, Groves J, Rayos G. Circulatory status and response to cardiac rehabilitation in patients with heart failure. Circulation 1996; 94: 1567-72
130. 130. Smith LE, Fabbri SA, Pai R, et al. Symptomatic improvement and reduced hospitalisation for patients attending a cardiomyopathy clinic. Clin Cardiol 1997; 20 (11): 949-54
131. 131. Shively M, Fox C, Brass-Mynderse NJ. Health-related quality of life as an outcome for patients with heart failure. J Cardiovasc Nurs 1996; 10 (2): 89-96
132. 132. Rideout E. Chronic heart failure and quality of life: the impact of nursing. Can J Cardiovas Nurs 1992; 3 (1): 4-8
133. 133. Wiklund I, Lindvall K, Swedberg K, et al. Self-assessment of quality of life in severe heart failure. Scand J Psychol 1987; 28: 220-5
134. 134. Wiklund I, Swedberg K. Some methodological problems in analysing quality of life data in severe congestive heart failure. J Clin Res Pharmacoepidemiol 1991; 5: 265-73
135. 135. de Vries RJM, Quere M, Lok DJA, et al. Comparison of effects on peak oxygen consumption. quality of life, and neurohormaones of felodipine and enalapril in patients with congestive heart failure. Am J Cardiol 1995; 76: 1253-8
136. 136. Guyatt GH. Measurement of Health-realted quality of life in heart failure. J Am Coll Cardiol 1993; 4: 185A-91A
137. 137. Nordbrock JE, Schwarz SW, Schoken DD. A comparison of two measures of quality of life for congestive heart failure. Heart Failure Soc 1998; Sep: 224
138. 138. Rich MW, Beckam V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1150-5
139. 139. Wolinsky FD, Wyrwich KW, Nienaber NA, et al. Generic versus disease-specific health status measures: an example using coronary artery disease and congestive heart failure patients. Evaluation Health Professions 1998; 21 (2): 216-43
140. 140. Wiklund I. Measuring quality of life in medicine. Scand J Prim Care 1990; 1 Suppl. 1; 11-4
141. 141. Deyo RA. The quality of life, research and care. Ann Intern Med 1991; 114 (8): 695-6
142. 142. Mayou R, Bryant B. Quality of life in cardiovascular disease. Br Heart J 1993; 69: 460-6